by John R. Fischer
, Senior Reporter | April 20, 2022
Owned by Siemens Healthineers, Corindus is looking to expand its reach with the opening of a new headquarters in Newton, Massachusetts.
The 77,000 square foot office for the precision vascular robotics manufacturer will be located at 275 Grove Street.
The headquarters will be the global Center of Excellence for Siemens Healthineers endovascular robotic technologies and facilitate manufacturing, development and administrative needs. “As we continue to advance our robotic-assisted platform, the new facility will support our mission to elevate the standard of care and increase access to cutting-edge treatment for coronary artery and neurovascular disease,” said Wayne Markowitz, executive vice president and head of Corindus, in a statement.
The facility is one of 15 new offices that Siemens is planning for the U.S. It also has a more modern and flexible workspace to help with growth and respond to employees. Within the space will be a fully equipped customer experience center that simulates a robotic setup in a hospital catheterization lab and a control room that include remote capabilities over various types of connections. The office will also provide physicians and cath lab personnel the opportunity to take part in interactive demonstrations of the CorPath GRX System and future innovations.
Approved for use in October 2016
, Corindus CorPath GRX comes with components that can aid in treating coronary, peripheral and neurovascular diseases. This includes a redesigned bedside unit, an extended reach arm and a touch screen display. The device allows users to control the guide catheter and robotically maneuver the guide wire and balloon or stent catheter from a remote console. Physicians can adjust the position of the guide catheter during percutaneous coronary intervention procedures.
It also has upgrades for improving its precision and workflow that broaden the range of procedures it can perform. It is the first FDA-cleared device that offers medical robotic precision for percutaneous coronary and vascular procedures. It is CE marked for neurovascular use in select markets.
Siemens acquired Corindus
in 2019 for $1.1 billion. Each of the precision vascular robotics makers obtained $4.28 in cash. The deal was expected to help grow the field of vascular robotics by combining Corindus with Siemens’ advanced therapies portfolio for reduced variability, improved efficiency, expanded access to care and improved patient outcomes.
The new headquarters is meant to further this objective and help Siemens reduce the impact of major diseases and intensify its clinical focus on coronary artery disease, stroke, lung cancer and liver cancer.
“The larger dedicated lab for research and development activities will enable our innovation teams to more effectively collaborate and scale our technology. Our new state-of-the-art clean room and a model shop will allow for quicker prototype machining and reduced development timelines,” said Per Bergman, vice president of research and development at Corindus.